The targeting of the glucagon-like peptide-1 (GLP-1) receptor for diabetes and obesity is not a novel strategy, with recent therapeutics showing efficacy in weight loss and glycemic control. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.